Hong Kong to Regulate Medical Gases as Pharmaceutical Products from June 2026

Hong Kong will begin regulating medical gases in cylinders as pharmaceutical products under the Pharmacy and Poisons Ordinance (Cap. 138) from June 14, 2026. Under the new framework, nitrous oxide and nitric oxide will be classified as prescription drugs, while other gases — including oxygen, nitrogen, carbon dioxide, helium, and medical air — must be registered before sale but will not be classified as poisons.

This regulatory change means overseas manufacturers must secure product registration before supplying medical gases to Hong Kong. For companies requiring expert support to determine classification, prepare dossiers, and navigate the Drug Office’s evolving requirements, contact Cisema today.

At a Glance: Key Changes to Hong Kong Medical Gas Regulation

The upcoming regulation introduces a pharmaceutical regulatory framework for medical gases in Hong Kong.

Key points include:

• Effective June 14, 2026: Medical gases in cylinders that meet the definition of pharmaceutical products must be registered before sale or supply in Hong Kong.
• Scope: Includes oxygen, nitrogen, nitrous oxide, nitric oxide, carbon dioxide, helium, medical air, and defined gas mixtures.
• Exclusions: In-situ gas production in healthcare facilities, oxygen concentrators, bulk liquefied gases in VIE tanks, non-medicinal uses, and certain diagnostic test gases.
• Penalties for noncompliance: Up to HK$100,000 and two years’ imprisonment.

Why Hong Kong Is Regulating Medical Gases as Pharmaceutical Products

After reviewing regulatory approaches in Mainland China, Australia, Canada, the EU, Singapore, the UK, and the US, Hong Kong’s Pharmacy and Poisons Board endorsed new controls to bring medical gases under the pharmaceutical framework. The updated regulation clarifies that gases meeting the pharmaceutical definition must undergo the same safety, efficacy, and quality evaluation required for all pharmaceutical products.

The development follows the regulatory timeline below:

• September 2023: Decision in principle to regulate medical gases as pharmaceutical products.
• November 2023 – January 2024: Public consultation period.
• June 14, 2024: Final decision announced and the two-year transition period begins.
• December 30, 2025: Department of Health reminder encouraging traders to complete registration ahead of schedule.
• June 14, 2026: Regulatory controls become fully effective.

For many overseas manufacturers, this marks a shift from treating medical gases as industrial products to meeting pharmaceutical-grade documentation standards.

New Drug Registration Requirements for Medical Gases in Hong Kong

Beginning June 14, 2026, companies supplying medical gases to Hong Kong must comply with formal drug registration requirements.

Under the new framework, medical gas products must be::

• Registered with the Pharmacy and Poisons Board before legal sale or supply.
• Supported by full documentation proving quality, safety, and compliance with relevant pharmacopoeial standards.

To support industry implementation, the Drug Office has published guidance documents outlining requirements for:

• Product specifications
• Labelling rules (including “For medical use only 只供醫療用途” and traceability)
• Stability and shelf life
• Container and closure systems
• Quality and storage considerations

These requirements apply regardless of where the gases are manufactured, meaning overseas manufacturers must ensure their products meet Hong Kong’s pharmaceutical regulatory standards.

Key Compliance Steps for Overseas Manufacturers

International manufacturers supplying medical gases to Hong Kong should begin preparing regulatory submissions well ahead of the 2026 deadline.

The following steps outline the key actions companies should take to determine regulatory scope, prepare documentation, and establish a compliant registration pathway.

Determine Whether Your Medical Gas Products Require Registration

Manufacturers should first determine whether their products meet Hong Kong’s definition of pharmaceutical products and whether their intended use triggers additional regulatory requirements.

Particular attention should be paid to gases such as nitrous oxide and nitric oxide, which will be regulated as prescription drugs.

Prepare a Hong Kong Medical Gas Registration Dossier

A typical Hong Kong medical gas registration dossier may include:

• Pharmacopoeial-compliant specifications (PRC, BP, EP, Ph. Int., JP, or USP)
• Stability data or justification for established gases
• Container and closure system specifications
• Labelling compliant with Hong Kong drug labelling requirements and medical-gas-specific statements (traceability, safety statements)

For highly stable gases, the Drug Office may accept scientific justification where full stability studies are not feasible.

Build a Hong Kong-Ready Regulatory Package

Overseas companies must designate a Hong Kong entity (often a subsidiary, distributor, or appointed representative) to act as the formal registration applicant and liaison with the Drug Office.

This entity becomes responsible for submitting the registration application and communicating with the regulator throughout the approval process.

Cisema can support companies throughout this process by:

• Preparing registration documentation
• Reviewing labelling for compliance
• Coordinating submissions aligned with the Drug Office’s published guidance

Stay Aware of Related Hong Kong Legislative Obligations

Although overseas manufacturers may not manage local storage or transportation, registration documentation should align with Hong Kong’s broader regulatory environment, including:

• Dangerous Goods Ordinance
• Fire Services Ordinance
• Boilers and Pressure Vessels Ordinance

Understanding these requirements helps ensure the registration dossier accurately reflects Hong Kong-specific compliance obligations.

Appoint a Hong Kong Registration Applicant or Local Representative

Hong Kong’s decision to regulate medical gases as pharmaceutical products strengthens patient safety and aligns the territory with mature regulatory systems internationally. For overseas manufacturers, the main challenge is adapting existing gas product data into pharmaceutical‑grade registration dossiers, but the transition also creates a more structured and predictable pathway for market entry.

With the effective date approaching, now is the ideal time to prepare documentation, clarify data needs, and ensuring your products remain eligible for the Hong Kong market.

Cisema can support you by helping interpret the new requirements, prepare well-structured dossiers, and liaise with the Drug Office throughout the registration process — ensuring your medical gas products are on track for approval.

Get in touch with Cisema today to begin your Hong Kong medical gas registration strategy.

Further Information

Explore Cisema’s services for Hong Kong Drug Registration.

About the Author: Jacky Li

Jacky Li is a Senior Manager at Cisema, based in Hong Kong and Taiwan. He has over a decade of experience in regulatory intelligence and market access, and serves as the lead supporting clients across Hong Kong, Mainland China (including the Greater Bay Area), and Taiwan, with a strong focus on pharmaceutical and medical device regulatory projects.

References

• Registration is required prior to the Sale of Medical Gases Starting From 14 June 2026, released on December 30, 2025
• Guidance Notes on Registration of Medical Gases, released in January 2026
• Guidance Notes on Manufacture, Wholesale, Storage and Transport of Medical Gases, released in June 2024